INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity.

@article{Yokota2007INNO406AN,
  title={INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity.},
  author={A. Yokota and S. Kimura and S. Masuda and E. Ashihara and J. Kuroda and Kiyoshi Sato and Y. Kamitsuji and E. Kawata and Yasuyuki Deguchi and Y. Urasaki and Y. Terui and M. Ruthardt and T. Ueda and K. Hatake and K. Inui and T. Maekawa},
  journal={Blood},
  year={2007},
  volume={109 1},
  pages={
          306-14
        }
}
Central nervous system (CNS) relapse accompanying the prolonged administration of imatinib mesylate has recently become apparent as an impediment to the therapy of Philadelphia chromosome-positive (Ph+) leukemia. CNS relapse may be explained by limited penetration of imatinib mesylate into the cerebrospinal fluid because of the presence of P-glycoprotein at the blood-brain barrier. To overcome imatinib mesylate-resistance mechanisms such as bcr-abl amplification, mutations within the ABL kinase… Expand
The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias
NS-187 (INNO-406), a Bcr-Abl/Lyn Dual Tyrosine Kinase Inhibitor
Tyrosine Kinase Inhibitors: The First Decade
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 61 REFERENCES
Mechanisms and implications of imatinib resistance mutations in BCR-ABL
In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor.
...
1
2
3
4
5
...